FGFR3 mutation/fusion — opens erdafitinib (THOR) pathway.

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

ID	`RF-UROTHELIAL-HIGH-RISK-BIOLOGY`
Type	Red flag
Status	pending_clinical_signoff
Diseases	`DIS-UROTHELIAL`
Sources	`SRC-EAU-BLADDER-2024` `SRC-NCCN-BLADDER-2025`

Red Flag Origin

Definition	FGFR3 mutation/fusion — opens erdafitinib (THOR) pathway.
Clinical direction	intensify
Category	high-risk-biology

Trigger Logic

{
  "any_of": [
    {
      "finding": "BIO-FGFR3-MUTATION",
      "value": "positive"
    },
    {
      "finding": "fgfr3_fusion",
      "value": true
    }
  ],
  "type": "biomarker"
}

Notes

THOR-2: erdafitinib superior in FGFR3+ post-platinum.

Used By

No reverse references found in the YAML corpus.